RO7440688

RO7440688 is an investigational oral small molecule inhibitor of Coagulation Factor XIa (FXIa) developed by Genentech and Roche. It is designed for the treatment and prevention of cardiovascular conditions, specifically thromboembolic disorders. By targeting Factor XIa, a protease in the intrinsic coagulation pathway, the drug aims to inhibit thrombus formation with a potentially reduced risk of bleeding compared to conventional anticoagulants that target the common pathway (such as Factor Xa or Thrombin). Clinical development has included Phase I studies evaluating the safety, tolerability, and pharmacokinetics of single ascending doses in healthy volunteers, as well as the impact of food on drug absorption.